Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080210 · ClinicalTrials.gov registry record · Phase 2
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
A Phase 2 study, sponsored by Savient Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00080210 is a Phase 2 study that has completed, run by Savient Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00080210, a Phase 2 study, has completed, sponsored by Savient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects must wash out of any uric acid-lowering agents for one week before being dosed, and must refrain from using such agents throughout the study.
Interventions
- DRUG Puricase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080210
The ClinicalTrials.gov registry entry for NCT00080210 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Savient Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Puricase is the first listed.
NCT00080210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080210 about?
NCT00080210 is a clinical study titled "A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy". This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects must wash out of any uric acid-lowering agents for one week before being dosed, and must refrain from using such ...
What is the current status of trial NCT00080210?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-03. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00080210?
The interventions under investigation include: Puricase (DRUG).
Who is sponsoring clinical trial NCT00080210?
This trial is sponsored by Savient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.